A multicenter, randomized, double-blind, controlled study of Shenyu Yangxin Capsule in the treatment of chronic heart failure based on multi-omics technology

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300077627

Enrollment

Unknown

Registered

2023-11-14

Start date

2023-11-15

Completion date

Unknown

Last updated

2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failure

Interventions

treatment group:The experimental group was treated with basic treatment plan + Shenyu Yangxin capsule

control group:The control group received basal treatment plus placebo

Groups of healthy people:not

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Treatment group and control group: ?Meet the diagnostic criteria for chronic heart failure in the 2022 AHA/ACC/HFSA Guidelines for Heart Failure Management; In line with the New York College of Cardiology (NYHA) heart function grading standards, grade II-III; ? Qi deficiency syndrome type, according to the "chronic heart failure TCM diagnosis and treatment expert consensus"; ? Age of onset: 40 years =70 years; ? The patient and/or authorized client give informed consent and sign informed consent. Healthy control group: ? No clinical symptoms, heart color Doppler ultrasound, BNP indicated no heart failure and other organic heart disease; ?Age: 40 years old =70 years old; ? The patient and/or authorized client give informed consent and sign informed consent.

Exclusion criteria

Exclusion criteria: ? Combined with severe liver and kidney dysfunction; ? Pregnant and lactating women, as well as patients with allergic constitution and a history of mental illness; ?Patients with acute myocardial infarction and unstable angina pectoris; Congenital heart defect; Valvular heart disease; Myocardial infarction in the past 2 months; Patients who have already installed pacemakers and implanted coronary arteries and other stents that are not suitable for MRI materials; ? Malignant tumor patients; ?Participants in other clinical trials; ? Researchers believe that patients are not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
NYHA cardiac function grading;Type B natriuretic peptide;	—

Secondary

Measure	Time frame
6 minute walk experiment (6MWD);Minnesota Scale;Chest x-ray;Echocardiography;Cardiac magnetic resonance;Western medicine degree of heart failure symptoms and signs;TCM heart failure syndrome score;	—

Countries

China

Contacts

Public ContactLuoGang

Hospital of Traditional Chinese Medicine affiliated to Southwest Medical University

1982luogang@163.com+86 136 7967 8969

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026